Clinical Trials Directory

Trials / Unknown

UnknownNCT06334458

Epigenomic and Machine Learning Models to Predict Pancreatic Cancer

Development of a New Algorithm to Integrate Clinical, Omics, DNA Methylation Biomarkers and Epidemiological Data for Early Detection of Pancreatic Cancer in High-risk Individuals

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
170 (actual)
Sponsor
European Institute of Oncology · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The goal of the multicentric and interdisciplinary IMAGene project is to pursue early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups, by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile. The study is a longitudinal, non-randomized exploratory clinical study. A total of 170 asymptomatic first-degree relatives of PC patients.

Detailed description

The study is a longitudinal, non-randomized exploratory clinical study. A total of 170 asymptomatic first-degree relatives of PC patients. The study population consists of 170 first (1st) degree healthy/asymptomatic relatives of patients with exocrine pancreatic cancer, where the patient satisfies one OR more of the following conditions: * was diagnosed with pancreatobiliary cancer \<50 years of age; * was diagnosed with pancreatobiliary cancer \>50 years of age AND personal history of any solid cancers. The CRPA will be assessed in 170 first degree relatives of PC patients, in whom the development of pancreatic cysts will be assessed by WB-MRI at baseline and at one year.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEarly diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groupsEarly diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile

Timeline

Start date
2023-02-03
Primary completion
2024-02-21
Completion
2024-12-31
First posted
2024-03-28
Last updated
2024-03-28

Locations

4 sites across 4 countries: France, Italy, Romania, Spain

Source: ClinicalTrials.gov record NCT06334458. Inclusion in this directory is not an endorsement.